Alberto Mussetti

Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT Key PointsTL1A-Ig+low-dose IL-2 pre-HSCT induces Treg expansion persisting early post-HSCT, diminishing GVHD, improving outcomes, and maintaining GVL.TL1A-

Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues, ameliorating GVHD post-HSCT url: ashpublications.org/blood/articl...

Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma Key PointsMAESTRO-Pool is a highly sensitive, tumor-informed assay capable of detecting ctDNA early after chimeric antigen receptor T cells.Reduction of ct

Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma url: ashpublications.org/bloodadvance...

Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study Key PointsRoutine prophylaxis with LVT does not reduce the risk of any-grade or severe ICANS after CAR-T therapy for LBCL.LVT may induce deeper, early ICAH

Routine prophylaxis with levetiracetam offers no benefit in CD19 CAR-T for LBCL: a multicenter propensity-matched study url: ashpublications.org/bloodadvance...

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 | NEJM Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein cholest...

Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 | New England Journal of Medicine www.nejm.org/doi/full/10....

Artificial intelligence in hematology In the last 2 years, the capabilities of artificial intelligence (AI) have progressed rapidly and are increasingly being integrated into hematology practic

Artificial intelligence in hematology url: ashpublications.org/blood/articl...

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma Key PointsWe developed a therapeutic cancer vaccine for MM against BCMA.Our findings revealed BCMA-specific immune response, providing the framework for it

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma url: ashpublications.org/blood/articl...

Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia Key PointsOlder MSDs or young HIDs lead to similar survival in older patients with AML.Young HID is associated with less relapse, whereas older MSD is asso

Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia url: ashpublications.org/bloodadvance...

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis Key PointsReal-world effectiveness and safety outcomes in patients with R/R MCL treated with brexu-cel are similar to those of the ZUMA-2 trial.The benefit

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis url: ashpublications.org/bloodadvance...

Microenvironmental regulation of solid tumour resistance to CAR T cell therapy - Nature Reviews Immunology The tumour microenvironment (TME) poses a significant obstacle to the success of chimeric antigen receptor (CAR) T cell immunotherapy in solid tumours. Here, the authors detail how both cellular and n...

www.nature.com/articles/s41...

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy Background Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). ...

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy jitc.bmj.com/content/13/1...

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023

24th OCT 2025 - Barcelona

Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.

#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution

lnkd.in/dBDXnaSK

In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | NEJM In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi...

mRNA for CART manufacturing for LES...

www.nejm.org/doi/full/10....

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT Key PointsAugmented CD47 expression on alloreactive donor T cells after HCT inhibits their phagocytosis by macrophages.Anti-CD47 treatment boosts phagocyto

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...

Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies Key PointsWU-CART-007, an allogeneic anti-CD7 chimeric antigen receptor T cell, established a manageable safety profile at the RP2D of 900 × 106 cells.WU-C

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...

A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept Key PointsPTCy+Aba arm is associated with less chronic GVHD and a favorable GRFS compared with methotrexate/tacrolimus.PTCy and Aba without a calcineurin i

ashpublications.org/bloodadvance...

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma Key PointsDespite similar CAR T-cell dynamics, patients with SLE experienced less severe adverse events after CAR T-cell therapy than those with B-NHL.In p

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...

Lymphoma accelerates T cell and tissue aging Hesterberg et al. show that lymphoma provokes marked and rapid changes in young T cells that recapitulate the transcriptional, epigenetic, and senescent features manifest in aged T cells, including ag...

www.cell.com/cancer-cell/...

Novel tool helps identify key targets to strengthen CAR NK cell therapies Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research...

www.mdanderson.org/newsroom/nov...

What Does It Take to Get Men to See a Doctor?

www.nytimes.com/2025/08/25/m...

Educational Strategies for Clinical Supervision of Artificial Intelligence Use | NEJM Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors provide an approach to clinical supervision that can mitigate the perils and ...

www.nejm.org/doi/full/10....

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy | NEJM A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...

www.nejm.org/doi/full/10....

Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy Zelig Eshhar, PhD, Fellow of the Academy of Immuno-Oncology (FAIO), passed away on July 3, 2025, at the age of 84. His passing is deeply personal to all of us and for the entire field of cancer immuno...

jitc.bmj.com/content/13/8...

Que la IA et diagnostiqui: el ChatGPT que ja fa servir el teu metge L'eina estarà a prova aquest any per donar suport als professionals sanitaris en la presa de decisions

www.ara.cat/1_535642

Opinion | You Are Contaminated

www.nytimes.com/2025/08/04/o...

Could Dementia Patients Benefit from an A.I. Companion?

www.nytimes.com/2025/07/31/w...

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability Key PointsUnique molecular features of Super-class HSCs were identified through analyses of single-clone serial transplants.Low expression of CD27 is a key

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability url: ashpublications.org/blood/articl...

Dear friends and colleagues,

We would love to have you join this year’s Transplant Complications Working Party Educational Meeting in Dubrovnik, Croatia, on the 1st-3rd of October. The EBMT

More information here:

www.ebmt.org/events/trans...

We look forward to seeing you in Dubrovnik!

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Key PointsLS, an emergent form of acute leukemia relapse after antigen-targeted therapy, primarily in B-ALL, has dismal outcomes.LS arises rapidly after im

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia url: ashpublications.org/blood/articl...